Humacyte, Inc. (HUMA)
- Previous Close
3.9300 - Open
3.9500 - Bid 3.8100 x 500
- Ask 3.8400 x 500
- Day's Range
3.6950 - 4.0300 - 52 Week Range
1.9600 - 5.6000 - Volume
1,475,113 - Avg. Volume
1,342,193 - Market Cap (intraday)
468M - Beta (5Y Monthly) 1.45
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0400 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.50
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
www.humacyte.comRecent News: HUMA
Performance Overview: HUMA
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HUMA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HUMA
Valuation Measures
Market Cap
454.90M
Enterprise Value
431.96M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
33.58
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-4.48
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.44%
Return on Equity (ttm)
-169.80%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-110.78M
Diluted EPS (ttm)
-1.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
80.45M
Total Debt/Equity (mrq)
143.84%
Levered Free Cash Flow (ttm)
-45.34M